This resource provides practical articles on Cost Management Strategies and links to locate them. These articles are provided to assist pharmacy managers and directors in dealing with the management issues focused on the affordability and accessibility of pharmaceuticals. Current topics covered in this new resource section include pharmacists' intervention strategies, formulary management strategies, population-based strategies, and anti-infective management strategies. Additional strategies will be added periodically to assist managers and directors in managing high-cost issues in pharmacy.

1. Anderson RJ. Cost analysis of a managed care decentralized outpatient pharmacy anticoagulation service. J Manag Care Pharm. 2004 Mar-Apr,10(2): 159-65
2. Carter C, Goldfarb NI, Hartmann CW, Roumm AR, Durkin M, et.al. Chronic pain management in managed care organizations: A national survey of medical directors. P and T. 2003; 28(3); 179-82, 184, 215.
   [No abstract available.]
3. Dranove D, Hughese EF, Shanley M. Determinants of HMO formulary adoption decisions. Health Serv Res. 2003; 38(1, Part 1); 169-190.
4. Simons WR. Comparitive cost effectiveness of angiotensin II receptor blockers in a US managed care setting – Olmesartan medoxoil compared with losartan, valsartan, and irbesartan. PharamcoEcon. 2003; 21(1); 61-74.
5. Yuan Y, Hay JW, McCombs JS. Effects of ambulatory-care pharmacist consultation on mortality and hospitalization. Am J Manage Care. 2003; 9(1); 45-56.
6. Carroll NV. How effectively do managed care organizations influence prescribing and dispensing decisions? Am J Manage Care. 2002; 8(12); 1041054.
7. Legorreta AP. Costs associated with common dual-control therapies for treating asthma in several managed care populations. J Manage Care Pharm. 2002; 8(5); 18-21.
8. Lexchin J. Effects of restrictive formularies in the ambulatory care setting. Am J Manage Care. 2002; 8(1); 69-76.
9. Suh DC, Okpara IR, Agnese WB, Toscani M. Application of pharmacoeconomics to formulary decision making in managed care organizations. Am J Manag Care. 2002 Feb;8(2):161-9.
10. Veenstra DL, Ramsey SD, Sullivan SD. A guideline for the use of pharmacoeconomic models of diabetes treatment in the US managed-care environment. PharamcoEcon. 2002; 20 Suppl 1, 21-30.
11. Weideman RA, Kelly RC, Kelley CL, Cryer B. COX-2-specific inhibitors: Prescribing patterns in a large managed care health system and strategies to minimize costs. Am J Manage Care. 2002; 8(10); 869-77.
12. Hedayati S, Kleinstiver PW. Predictive cost analysis model for estimating formulary impact of new products in managed care. J Manage Care Pharm. 1998; 4(Nov-Dec); 585-590.
    [No abstract available.]
13. Blissenbach HF. Use of cost-consequence models in managed care. Pharamcotherapy. 1995 (Sep-Oct);15(5Pt 2): 59S-61S.